ADAG

ADAG

Adagene Inc. American Depositary Shares

$1.950+-0.000 (-0.000%)

Reaalajas hind

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$1.950

Kõrge

$1.950

Madal

$1.950

Maht

0.00M

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Seotud uudised

GlobeNewswire

Adagene to Present at Jefferies Global Healthcare Conference 2025

SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that

Vaata rohkem
Adagene to Present at Jefferies Global Healthcare Conference 2025
GlobeNewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR)

Vaata rohkem
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting